Molecular determinants of the inflammatory breast cancer phenotype

ONCOLOGY

Volumn 22, Issue 14, 2008, Pages 1556-1561

  Houchens, Nathan W ^a   Merajver, Sofia D ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ONCOPROTEIN; PROGESTERONE RECEPTOR; PROTEIN P53; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOC GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; WNT INDUCIBLE SIGNALING PATHWAY PROTEIN 3;

ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER INCIDENCE; CANCER SURVIVAL; DISEASE COURSE; DISEASE MARKER; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GEOGRAPHIC DISTRIBUTION; HISTOPATHOLOGY; HUMAN; INFLAMMATORY BREAST CANCER; MOLECULAR GENETICS; NONHUMAN; ONCOGENE; PHENOTYPE; PROGNOSIS; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR;

AFRICAN AMERICANS; BREAST NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PHENOTYPE; PROGNOSIS; RECEPTOR, ERBB-2; RHO GTP-BINDING PROTEINS;

EID: 59349120508     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Hance KW, Anderson WF, Devesa SS, et al: Trends in inflammatory breast carcinoma incidence and survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute. J Natl Cancer Inst 97:966-975, 2005.
2. Rosen PP: Rosen's Breast Pathology, 2nd ed. Philadelphia, Lippincott Williams & Wilkins, 2001.
3. McCarthy NJ, Yang X, Linnoila IR, et al: Microvessel density, expression of estrogen receptor α, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res 8:3857-3862, 2002.
4. Alpaugh ML, Tomlinson JS, Shao Z, et al: A novel human xenograft model of inflammatory breast cancer. Cancer Res 59:5079-5084, 1999.
5. Singletary SE, Allred C, Ashley P, et al: Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20:3628-3636, 2002.
6. Jaiyesimi IA, Buzdar AU, Hortobagyi G: Inflammatory breast cancer: A review. J Clin Oncol 10:1014-1024, 1992.
7. Wojcik BE, Spinks MK, Optenberg SA: Breast carcinoma survival analysis for African American and white women in an equal-access health care system. Cancer 82:1310-1318, 1998.
8. Newman LA, Mason J, Cote D, et al: African-American ethnicity, socioeconomic status, and breast cancer survival: A metaanalysis of 14 studies involving over 10,000 African-American and 40,000 White American patients with caxcinoma of the breast. Cancer 94:2844-2854, 2002.
9. Yood MU, Johnson CC, Blount A, et al: Race and differences in breast cancer survival in a managed care population. J Natl Cancer Inst 91:1487-1491, 1999.
10. Schwartz KL, Crossley-May H, Vigneau FD, et al: Race, socioeconomic status and stage at diagnosis for five common malignancies. Cancer Causes Control 14:761-766, 2003.
11. Henson DE, Chu KC, Levine PH: Histologic grade, stage, and survival in breast carcinoma: Comparison of African American and Caucasian women. Cancer 98:908-917, 2003.
12. Lo AC, Kleer CG, Banerjee M, et al: Molecular epidemiologic features of inflammatory breast cancer: A comparison between Egyptian and US patients. Breast Cancer Res Treat 112:141-147, 2008.
13. Ethier SP: Human breast cancer cell lines as models of growth regulation and disease progression. J Mammary Gland Biol Neoplasia 1:111-121, 1996.
14. Shirakawa K, Tsuda H, Heike Y, et al: Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res 61:445-451, 2001.
15. Kaufman M: Review of known prognostic variables. Results Probl Cell Differ 140:77-87, 2000.
16. Paradiso A, Tommasi S, Brandi M, et al: Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer 64:1922-1927, 1989.
17. Le MG, Arriagada R, Bahi J, et al: Are risk factors for breast cancer similar in women with inflammatory breast cancer and in those with non-inflammatory breast cancer? Breast 15:355-362, 2006.
18. Charafe-Jauffret E, Tarpin C, Bardou VJ, et al: Immunophenotypic analysis of inflammatory breast cancers: Identification of an 'inflammatory signature'. J Pathol 202:265-273, 2004.
19. Guerin M, Gabillot M, Mathieu MC, et al: Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: Prognostic significance. Int J Cancer 43:201-208, 1989.
20. Turpin E, Bieche I, Bertheau P, et al: Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene 21:7593-7597, 2002.
21. Aziz SA, Pervez S, Khan S, et al: Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: A unique clinical experience. Breast J 7:398-404, 2001.
22. Moll UM, Riou G, Levine AJ: Two distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion. Proc Natl Acad Sci USA 89:7262-7266, 1992.
23. Riou G, Le MG, Travagli JP, et al: Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst 85: 1765-1767, 1993.
24. Faille A, De Cremoux P, Extra JM, et al: p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer 69:1145-1150, 1994.
25. van Golen KL, Davies S, Wu ZF, et al: A novel putative low affinity insulin-like growth factor-binding protein LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 5:2511-2519, 1999.
26. Hall A: Rho GTPases and the actin cytoskeleton. Science 279:509-514, 1998.
27. Hakem A, Sanchez-Sweatman O, You-Ten A, et al: RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev 19:1974-1979, 2005.
28. van Golen KL, Wu ZF, Oiao XT, et al: RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2:418-425, 2000.
29. Wu M, Wu ZF, Kumar-Sinha C, et al: RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cells. Breast Cancer Res Treat 84:3-12, 2004.
30. van Golen KL, Wu ZF, Oiao XT, et al: RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 60:5832-5838, 2000.
31. Kleer CG, Zhang Y, Pan Q, et al: WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene 21:3172-3180, 2002.
32. Kleer CG, Zhang Y, Pan Q, et al: WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer. Neoplasia 6:179-185, 2004.
33. Kleer CG, Zhang Y, Pan Q, et al: WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res 6:110-115, 2004.
34. van golen KL, Bao L, Di Vito MM, et al: Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther 1:575-583, 2002.